What we do Orchid Pharma Ltd is an integrated pharmaceutical company specializing in antibiotics and veterinary products, with manufacturing and R&D facilities compliant with global standards. |
Founded in 1,992 |
Market share One of the world's few USFDA approved cephalosporin API manufacturers with strong global presence. |
Problem solved Provides vital anti-infective medicines addressing bacterial and fungal infections worldwide. |
Top clients or who we serve Pharmaceutical companies, healthcare providers globally in human and veterinary sectors; operates B2B and B2C. |
Key management Manish Dhanuka (Managing Director), Mridul Dhanuka (Whole-Time Director) |
Our journey and innovations Pioneer in sterile cephalosporins and first Indian New Chemical Entity approved in US and Europe; acquired Allecra Therapeutics assets. |
Where we operate India, USA, Europe, Japan, Africa, and other international markets. |
Top products or what we offer Cephalosporin APIs and finished dosage forms across five generations; novel antibiotic Enmetazobactam under brand Orblicef. |
Top brands Orblicef - India’s first novel antibiotic; wide range of cephalosporin APIs and anti-infective formulations. |
Raw materials needed Key raw materials include advanced pharmaceutical chemicals for API synthesis like 7ACA and other intermediates. |
Raw materials supplier Supplied through integrated internal manufacturing and external vendors; ongoing backward integration underway. |
Recurring vs cyclical contribution Revenue largely from recurring sales contracts of APIs and formulations with some cyclical investment in R&D and capacity expansion. |
Our industry position Market leader in cephalosporin API manufacturing with global regulatory approvals and extensive export footprint. |
Financial highlights FY25 revenue Rs 921.93 Cr, net profit Rs 99.66 Cr; steady revenue growth; invested Rs 31.57 Cr in capital expenditure. |
Geographical revenue split India contributes Rs 180.91 Cr; Rest of World Rs 728.23 Cr in FY25 revenue. |
Order book - |
Whats driving growth Growth driven by global antibiotic demand, proprietary drug ownership, capacity expansions, and strategic acquisitions. |
Our future plans Expand sterile and oral product capacities, backward integration, commercialization of novel antibiotics globally. |
Our green promise Implements zero liquid discharge, advanced waste and emission treatments, promotes sustainability and community health programs. |
Our people and values Committed to safety, employee development, ethical practices, inclusion, and robust corporate governance. |
Key challenges ahead Regulatory compliance, antibiotic resistance trends, competitive market, and managing large scale R&D and capital projects. |
Interesting facts Only Indian company to invent a new chemical entity approved in western markets; first novel antibiotic molecule ownership secured globally. |
Risks and strategy Mitigates regulatory, market, and operational risks via strong compliance, diversification, innovation, and strategic partnerships. |
